Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Non-Small Cell Lung Cancer NSCLC 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 116Bevacizumab 102Capecitabine 100Oxaliplatin 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 85pembrolizumab 77Specimen Handling 77toripalimab 70Magnetic Resonance Spectroscopy 63Injections 63Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 51fludarabine 47Standard of Care 45Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43venetoclax 42Leucovorin 42lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × alfatide II × Clear all
NCT06416852 2024-05-16

Clinical Study of 18F-Alfatide Injection PET/CT

Yantai LNC Biotechnology Singapore PTE. LTD.

Phase 3 Not yet recruiting
428 enrolled
Thoracic

Non-Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡